Member Info for MR.Spacetomato

Russia might want to hit the "reset" button after this mess, but let’s not ignore the real wild cards in play—Trump and Putin. Their "bromance" has people raising eyebrows, and the timing of these calls? Suspicious, to say the least.

Trump-Putin Connection

The Call Heard 'Round the World: Trump reportedly had a cozy little chat with Putin, allegedly telling him to cool it in Ukraine. Of course, the Kremlin denies it faster than a kid caught sneaking cookies.

Strategic Whispering: If Trump’s back in charge, you can bet Russia’s banking on a softer approach from the U.S.—less NATO posturing, fewer sanctions, maybe even a handshake deal under the table.

Scholz Jumps In

Coincidence or Coordination? Right after the alleged Trump-Putin chat, German Chancellor Olaf Scholz picks up the phone and asks Putin to make nice. Scholz hasn’t dialed Putin in nearly two years, so why now?

Mixed Messaging: Scholz talks peace while Zelensky fumes, saying this undermines efforts to isolate Putin. Honestly, it’s like watching a diplomatic soap opera—who’s siding with whom today?

What It All Means

Putin’s Playbook: If Russia’s hedging on a Trump comeback, they might feel emboldened to drag their feet, expecting better terms down the line.

Western Divisions: Scholz’s move hints at cracks in the unified front. Not everyone’s playing the "maximum pressure" game anymore.

Ukraine’s Spotlight: Zelensky’s walking a tightrope here, trying to keep allies aligned while staying in the global sympathy zone.

Bottom line: The war’s chessboard just got a lot more complicated. Between Trump’s shadow, Scholz’s sudden call, and Putin’s usual power plays, this isn’t just a question of "business as usual" anymore—it’s a masterclass in geopolitical poker.

JEMA's price jump isn’t magic; it’s investor hype, plain and simple. Trump gets elected, people start dreaming he’ll go soft on Russia, and boom — shares tied to Russian assets, like JEMA, shoot up. Why? Investors are gambling that Russian sanctions might ease up, which means assets JEMA's holding, like a sprinkle of Lukoil and a dash of Gazprom, could suddenly be worth a lot more.

Now, hold on. JEMA’s still dragging some serious baggage — legal messes, and the fact they’re operating in sanction-prone markets. So sure, the price might be up, but this isn't some golden ticket. Make sure you're looking past the headline hype before you jump in, because this uptick could be here today, gone tomorrow.

Thanks for the tip, though. Got out 2 days ago. :0)

One of the best investments i made after a tip.

Love Trump!

Needed = Neeew

Alright, let’s connect the dots here on how peace could mean real relief for the UK economy, especially on things like oil, gas, and everyday living costs. So, here’s the big picture: if a peace deal is achieved in Ukraine, it’s not just about ending the conflict—it’s about unsticking all the economic blockages that the war, and the sanctions, have put in place.

First off, think about energy prices. The war in Ukraine has been like a wrench in the gears of global oil and gas supply. With Russia sidelined by sanctions, Europe had to scramble for new energy sources, which drove up prices everywhere, especially in the UK, where we felt that impact straight in our energy bills. Peace would logically lead to a loosening of these restrictions, meaning Russian oil and gas might re-enter the market. That would stabilize supply, drive prices down, and take some pressure off the UK energy market. Average Joe starts seeing a drop in gas and electricity bills because demand isn't outpacing a limited supply anymore.

Then there’s the UK budget and overall cost of living. Lower energy prices mean lower production costs for UK businesses—everything from manufacturing to food production and transportation gets cheaper. This cascades down to cheaper goods on the shelves. Suddenly, inflation, which has been hammering everyone, could cool off as well. The government, in turn, wouldn’t have to throw quite as much money into energy subsidies or inflation relief measures, which frees up cash in the budget. It’s a win-win: more budget flexibility and less strain on the taxpayer.

Now, if you look back, similar situations have played out before. After conflicts, easing sanctions and restoring trade relationships have usually paved the way for economic recovery. After the Gulf War, for example, oil production resumed, prices dropped, and economies breathed a bit easier. So, if peace comes to Ukraine and sanctions lift, we could see a path to some actual relief—not just for corporate players but for regular folks who are sick of paying through the nose for basics. It’s the kind of trickle-down that actually works because it’s based on global supply and demand, not wishful thinking.

ST

Needed, "He can most likely ‘force’ peace, with the war ended there will be no justification for continued sanction of Roman Abromovich nor Evraz".

Alright, let’s get into this. Here’s the optimistic spin with a bit of history and a dash of logic:

Look, you’re onto something here. If Trump—or anyone with enough global clout—can lean on both sides hard enough, getting them to lay down arms, then the sanctions, in theory, should start looking pointless. Sanctions, after all, are supposedly a means to an end. They’re like the giant “time out” chair in the global playground—meant to pressure change. So, if you’ve reached that change, keeping sanctions around just feels like kicking someone who’s already shaken hands and called a truce.

Now, history has plenty of examples where, after peace talks, sanctions were dialed back or outright removed to support economic rebuilding. Take South Africa in the '90s. Once apartheid was dismantled, international sanctions got tossed because they’d done their job—no one was pretending they were still relevant. Even in the Cold War days, Nixon shook hands with China, and the sanctions thawed out. Why? Because peace and economic normalization are two sides of the same coin. It’s a case of common sense: you want stability, not lingering resentment.

So, if peace in Ukraine is truly achieved, there’s a logical argument that holding onto sanctions would do more harm than good, especially when big players like Trump are likely to push for economic incentives to cement that peace. It’s not about coddling oligarchs or cutting Evraz some slack—it’s about setting up a functioning post-war economy.

ST

Oh, Jacobjohn, you're getting a bit predictable—and honestly, you’re boring me. I mean, how many times are we going to go over this same song and dance? You’re still banging on about “1p dilution” and how this is somehow the end of the road for Polarean. We get it; you’re desperate to see this share dip just so you can scoop it back up. Classic amateur move. If I had more free time, maybe I’d humor you, but we both know what’s really going on here.

It’s actually funny, Jacobjohn—you’re the textbook example of why Google is littered with warnings about day traders. Your approach? Trying to shake up investors with your overblown “concerns” in the hopes of a quick buy-in opportunity. But let’s get real: if you’re that fixated on temporary dips, you’re missing the point entirely. Polarean’s not a penny stock to play games with; it’s working with big players like Philips and making strides in FDA-backed tech. So while you’re hanging your hopes on share price micro-movements, long-term investors see a path to actual medical impact—and, yes, actual returns.

The bit about “ruinous dilution” is tired, Jacobjohn. If you can’t handle the basics of medtech R&D, maybe this isn’t your sandbox. Companies building transformative technology need capital—it’s not news. And while you sit there clutching at straws, anyone with an ounce of foresight sees the long game Polarean’s playing.

So look, I could spend more time explaining this, but frankly, I have better things to do. If you’re this desperate to drive down the price, maybe it’s time to rethink the whole “day trader” routine. Google’s data doesn’t lie, mate: most people trying your little game end up losing more than they gain. So, I’ll leave you to it—some of us have real investments to watch grow.

To the other bulletin board members, my apologies for cluttering the post space. But this Jacob isn't all he seems to want to convey.

ST

Ah, Jacobjohn, back at it with the fertilizer jokes—clearly working hard to keep his “strong sell” pitch polished. His comments are a classic case of trying to rattle the cages without actually understanding the value under the surface. Let’s break down this thin attempt at “analysis.”

First off, his claim about “no news” and the financials: Jacobjohn’s conveniently skipping over the fact that Polarean’s long COVID study is part of groundbreaking research, which is by nature not a one-and-done announcement. Clinical trials and FDA submissions take time, and it’s not like Polarean’s releasing a quick-fix app here—they’re advancing a technology that could reshape respiratory care. Real investors get that medical tech isn’t a weekly newsletter. The fact that Polarean’s even been in these studies, supported by heavyweights like Oxford and Sheffield, shows it’s on the radar for serious healthcare advancements.

Then he talks about the cash runway, tossing in “dilution” like he’s discovered the Holy Grail of stock scare tactics. Let’s be honest: R&D in medtech isn’t a free lunch. Polarean’s focus is on expanding cutting-edge imaging tech that literally couldn’t exist in a low-budget, zero-risk vacuum. Investors who understand medtech know that dilution is par for the course to fuel development—especially when it’s for something groundbreaking like hyperpolarized xenon MRI. If you’re the sort who panics at the sight of “dilution,” maybe stick to index funds.

And let’s talk about this “sugar daddy” theory. Jacobjohn seems to think Polarean’s entire roadmap hinges on getting a “hand holder” to carry them through. Polarean isn’t looking for a lifeline; it’s securing partnerships with industry leaders like Philips and Siemens because this tech has solid ground to stand on. Partnering with the big guns isn’t a sign of desperation—it’s strategic. These are powerhouse names in medical imaging, not venture capitalists bailing out a startup. Jacobjohn’s attempt to spin these partnerships as a weakness is, frankly, embarrassing.

Finally, he wants “commercial news.” Funny thing is, he’s missing the whole point: Polarean’s developments aren’t a product churn. They’re milestones. Each step, every trial and every partnership, is building something that changes healthcare, not just the stock ticker. Real investors understand this. So, Jacobjohn, maybe leave the tomato puns and sensationalism aside—some of us actually see the bigger picture.

Jacob, your so simplistic in your attempts to deramp that I feel you are trying to punch above your pay grade.

ST

ah, jacobjohn—still running on autopilot, i see. he’s spinning some half-baked lines about “perennial pump and dumping” as though polarean’s advanced imaging tech were some novelty item on late-night tv. let’s break down his laughable points.

first, the image quality bit. he’s rambling about human eyes being the measure of quality, as if that negates the tech polarean’s team has developed. polarean’s hyperpolarized xenon mri isn’t about giving patients a clearer vacation photo—it’s pioneering precision in detecting long covid abnormalities that traditional imaging just can’t see. when you’re talking about detecting life-altering symptoms, it’s a whole other league compared to run-of-the-mill ct scans or basic mri. this technology tracks gas transfer on a molecular level. so, jacobjohn can s***** all he likes, but it won’t let him “see” the invisible pulmonary impairments that polarean’s imaging can.

then, the commercialisation question—“where’s the news?” he says, like the tech world revolves around his schedule. polarean isn’t rushing half-finished products to market for the sake of people like him. hyperpolarized xenon mri has cleared key hurdles, including an fda nod and dedicated reimbursement. that’s a serious vote of confidence from regulatory bodies, meaning clinicians see it as viable and valuable. polarean is building partnerships with the likes of philips and ge—companies that don’t mess around with “pumps and dumps.” this is big-league validation, not some fanfare for jacobjohn’s quick-buck fantasies.

he also trots out the “old study” card with that 2022 article, blissfully ignoring that research is cumulative. this wasn’t a pr blitz—it was groundwork that validated the tech’s capabilities, which, by the way, weren’t available with standard tests. each study adds layers of understanding, and the explain study is still active, gathering more data. it’s one thing to brush off early research, but he’s essentially ignoring how the technology has progressed since. polarean’s team isn’t here to impress armchair critics but to solve real, complex issues in respiratory health.

and finally, his “space ganja” quip—good one, mate, you’ve really nailed it. but maybe, just maybe, while he’s lost in orbit with his one-liners, he missed the fact that polarean’s imaging tech is entering major hospitals and universities, trusted by top-tier researchers. that’s not stoner talk; that’s real-world impact. so, jacobjohn, while you’re having fun with your little puns, polarean’s out there changing the landscape of pulmonary medicine.

sometimes i feel bad replying to you. i have this feeling i a slapping a kid on 1st grade who keeps coming back for more. :0(

Alright, let’s unpack Jacob’s “analysis,” shall we?

First up, Jacob’s big point here is that GE Healthcare’s head of MRI visited Sheffield two weeks ago. Groundbreaking stuff, Jacob. It’s a visit, not a takeover, but let’s all stop the presses because someone at GE boarded a train to Yorkshire. Look, corporate visits are as routine as a Starbucks run, and they’re hardly a sign of a competitive advantage. But here we are, with Jacob convinced he’s discovered the smoking gun against Polarean, as if GE wouldn’t visit if Polarean had anything worthwhile.

Then, there’s the whole, “Time isn’t a bad thing when showing Polarean isn’t unique” bit. Jacob’s giving off strong “too much coffee, not enough evidence” vibes here. Sure, time isn’t bad—except when you're spending it trying to unearth some conspiracy about Polarean’s relevance. The fact is, time spent nitpicking the market leader doesn’t make competitors’ products any better; it just makes you look desperate to find flaws.

And here’s the gem: “I’m sure you’ll agree the image quality was already better in 2019.” Ah, yes, I’m sure we’ll all agree... based on zero specifics or data, just vibes. Jacob’s taking a shot in the dark with a throwaway line about image quality, with nothing to back it up. It’s like saying, “I’m sure my ancient Polaroid’s images are better than your iPhone.” Feels like someone’s brain cells were on vacation when that “analysis” came together.

Finally, we’ve got the “You keep ramping; I’m analysing the wider picture.” Jacob, if your “wider picture” is built on personal hunches, corporate visits, and hypothetical image quality from five years ago, it might be time to re-evaluate your “analysis.”

ST

Nadroj, gracias for your link. I did some work on the video interview. Impressive:

Alan Huang’s New Role at Polarean: The “All-In” Approach to Lung Scans and Partnerships

So, Alan Huang, this proper medtech genius, has just jumped into Polarean Imaging as the VP of Sales. Now, imagine a bloke who’s spent his whole life working with MRI machines, doing the science-y stuff at Johns Hopkins, then managing a $300 million MRI business at Philips. What’s he going to do at Polarean? Well, he’s ready to go all-in selling these hyper-polarized gas scans for lungs – like he's found the Holy Grail of radiology.

What’s the Plan?

Here’s his strategy, and, no surprise, it’s got layers. First, he’s squeezing every dollar out of existing customers. Why? Because they’ve already shelled out for the tech – might as well get them to use it more, right? He’s got about 21 customers in the bag, and he’s telling them to ramp it up, especially in clinical and research.

Big Plans for Big Partnerships

Now, you know Alan doesn’t just stop at a few hospitals. He’s got a list of the big boys – Philips, GE, Siemens – and he’s all over them to push this tech into every hospital they’re in. Imagine the poor sales reps at GE and Siemens who are about to get a call about “amazing new lung imaging.” Honestly, Alan’s determined to make sure every radiologist knows that these gas scans are the new black.

Next Steps? Expansion and World Domination, Sort Of

Alan’s not even pretending to stop at the U.S. Once he’s milked that for all it’s worth, he’s going global. He's looking for any company willing to help him spread hyper-polarized xenon like it’s going out of fashion.

For POLX Investors?

If you’re holding POLX shares, here’s what you’re banking on: Alan’s non-stop sales pitch, his “high-potential” customer list (apparently 100 hospitals that just “need” this tech), and every major MRI company taking his calls. If he can get everyone on board, POLX might just turn a few heads on Wall Street.

DYM, for polx shareholders, the recent surge in NHS admissions for respiratory issues underscores a real opportunity. With the NHS under pressure to manage conditions like asthma and COPD more efficiently, Polarean’s imaging technology could offer precisely what’s needed: a tool for earlier, accurate diagnoses that can help streamline patient care and reduce emergency department strain.

With respiratory health now a clear priority, Polarean is well-positioned to play a key role, making it a timely and relevant opportunity in both healthcare impact and investment potential.

Desperate Jacob,

Oh, "three more tranches of dilution", is it? And they need a "sugar daddy"— brilliant!

Listen, mate, Polarean’s not out here prowling for handouts or waiting for a fairy godfather to sprinkle some cash their way. They’re developing cutting-edge medical tech, not launching a dating app for investors!

And as for this risk versus reward" bit—what, you thought groundbreaking healthcare was a guaranteed win from day one? Not every company gets to take the easy road to the moon. But look at it this way: if it’s getting you this riled up, maybe there’s something to it, yeah? And then there's Brit Bulla with its ‘SELL’ recommendation. Oh, yeah, let’s all panic because Brit Bulla says so—terrifying, that! They’re not ‘manipulating to their heart’s content,’ they’re just giving you a bit of drama to spice up the newsletter.

End of the day, if you think it’s all doom and gloom, maybe sit this one out. Just means more for those of us who’ve actually read up on what Polarean’s doing.

Jacob, is that a stammer that you have to say the same thing twice? We heard you first time round.

Oh, they’re ‘dragging their feet,’ are they? Classic! Look, Polarean’s playing a high-stakes game here, not hosting a bake sale. This isn’t a company tossing out products willy-nilly; they’re dealing with complex tech, clinical trials, regulatory hoops, and a healthcare system that moves about as fast as a glacier.

Sure, forecasts set a high bar for 2025—but that's because they're aiming to lead in an actual clinical market, not just churn out gadgets. ‘Commercial traction’ takes time when you’re working with hospitals and doctors, not online shoppers. So, yeah, news will shift things, but let's keep a bit of perspective before writing off Polarean for not moving at light speed. Quality and real innovation don’t happen overnight, alright?"

Bless

Jacob, Jacob. You really smacks of desperation now, bear candles and all.

Oh, Xemed’s ‘competition’ for Polarean? Really? Let's have a look, shall we? Polarean is out there with FDA-approved xenon hyperpolarizers, actually in hospitals, working with top researchers, doing real diagnostic magic in pulmonary imaging. And Xemed? Filing in Canada, poking around Europe with some niche research setups—good for them, bless ‘em. But this isn’t ‘competition’; it’s like comparing a Swiss Army knife to an MRI machine.

Polarean’s tech is clinical-grade, targeted, and already making a difference in places that matter. Xemed isn’t even in the same ballpark for real clinical use. But sure, let’s pretend the market’s ‘crowded’ because a few labs in the world bought a hyperpolarizer from them. If anything, Polarean’s just more like the future of diagnostic imaging—and Xemed? Well, maybe Jules Verne would approve.

It’s a compelling point – POLX does seem undervalued considering its assets and growth potential, especially with the recent advancements in Xenon imaging. The current market valuation doesn’t fully reflect the depth of their technology, strategic partnerships, and FDA backing, which sets the stage for a significant re-evaluation as new developments come through. The gap could indeed close swiftly with the right news or momentum, especially if we see stronger traction in adoption or new deals. Interesting to see how undervalued assets here can create unique entry points for investors willing to look beyond the surface valuation metrics. Definitely one to keep an eye on!

ST

Interesting points, John!

There’s definitely a lot in the pipeline for Polarean, and it’s encouraging to see the potential around the Xenon systems, partnerships, and approvals. The 20p+ target for 2025 sounds ambitious but not impossible if they can secure those key partnerships and scale internationally. That said, do you have any recent RNS updates or sources on the multi-site orders and U.S. partnerships? Would be good to understand more about the timeline for those, especially with the acquisition rumors floating around. Always nice to see optimism, but a bit more info on the specifics would really help ground the projections. Fingers crossed for the next wave!

ST

DT, It looks like Polaris Quantum Biotech isn’t a UK-registered company—there’s no listing for it on Companies House. They’re actually based in the U.S., in Durham, North Carolina, so they likely operate from there.

As for any connection between Polaris and NVision, there doesn’t seem to be one. Polaris Quantum Biotech focuses on quantum computing for drug discovery, aiming to speed up finding lead molecules for new drugs. NVision, on the other hand, works in MRI imaging, using hyperpolarization for better metabolic imaging, especially for things like early cancer detection. So, while both are in the biotech field with some quantum tech overlap, they’re separate companies with different focuses and no formal link that I could find.

Malvern,

Picture this: a day trader, sitting there in their pyjamas at noon, eyes glued to a screen, convinced they’re the next Wall Street genius. And by convinced, I mean clinging to that belief like a life raft. Statistics? Google it, mate—most of these traders lose more than they gain. But that doesn’t stop them from charging onto bulletin boards, all proud, shouting, “I just bought in! Big gains coming!” as if anyone else cares. They’re hoping for some poor saps to follow, like a dodgy pied piper for muppets.

Then the plot thickens. They sell off, expecting the price to crash…and what happens? The price goes up. So now, instead of slinking off to pray to their trading gods or whatever, they’re back on the board, typing up these frantic, tragic posts trying to spook people into selling. It's like they’re hoping a handful of desperate messages will somehow tank the stock price through sheer power of cringe. Honestly, it’s like watching someone try to stop a train by shouting at it.

Polarean Imaging plc and NVision Imaging Technologies may sound related since both work in advanced MRI, but they’re actually focused on different areas. Polarean specializes in imaging lung function with a unique approach using hyperpolarized xenon-129 gas to create detailed, non-invasive images of lung ventilation. This is particularly valuable for assessing lung diseases without using radiation.

On the other hand, NVision’s POLARIS system takes hyperpolarization in a different direction, focusing on metabolic imaging. Their tech is aimed at oncology, helping doctors see metabolic changes in cancer patients, which can be key for early treatment decisions.

So, while they share some common ground with hyperpolarization technology in MRI, Polarean is all about lung health, whereas NVision’s POLARIS targets cancer diagnostics. They’re addressing very different needs in the medical imaging world, so they’re not directly related in terms of products or operations.